Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus letrozole in first-line HR-positive, HER2-negative advanced breast cancer
2016-002556-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ribociclib and letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Clinical Benefit Rate (CBR) after 24 weeks. Started Aug 2016; status: completed.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002556-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002556-24.